Is it good to take repaglinide for diabetes

For type 2 diabetes, repaglinide can generally be used.

The representative oral drugs for diabetes and their approximate effects are as follows:

1. Sulfonylureas: on behalf of the drug glipizide, the main function: to promote insulin secretion (there are cells that secrete insulin).

2. Meglitinide: The representative drug is repaglinide you asked, which also promotes insulin secretion.

3. Biguanides: Metformin, the representative drug, has the main effect: inhibiting liver glucose output, improving insulin sensitivity, and increasing glucose uptake and utilization. (is the current first-line medication).

4. Thiazolidinediones: representative drugs rosiglitazone and pioglitazone. Main effect: Increase the sensitivity of tissues to insulin.

5. Glucosidase inhibitor: representative drug acarbose. Main effect: Delay the absorption of sugar.

The encyclopedia of chronic diseases has detailed explanations, and you can consult them when you have time. After all, knowing oneself and knowing one's opponent will not be defeated in a hundred battles.

In addition, chronic diseases, as the name suggests, can have a long course of disease, so they need to be well controlled. It's the same as women's maintenance, 40-year-old is not old, and 30-year-old is like 60-year-old. The same is true for chronic diseases, which are not much different from healthy people if they are well controlled, and it is difficult to say if they are not well controlled.

Finally, please note that you must seek medical attention and hospitalization adjustment when adjusting the medication! Take your medication regularly as instructed by your doctor! Don't buy it yourself!

Eating less and poor blood sugar control will lead to early complications and shorten lifespan! There are even life-threatening acute complications! If your blood sugar drops too low after eating too much, you may suffer from hypoglycemic shock or even death!

Please be sure to adjust the medication according to the doctor's arrangement after hospitalization and diagnosis!

This depends on the type of diabetes There are types 1 and 2, type 1 diabetes patients (insulin-dependent) such patients cannot secrete insulin on their own, and the insulin-producing cells of the pancreas in the body have been completely damaged, so they have completely lost the function of producing insulin, and can only rely on insulin injection, so they eat repaglinide in vain. (repaglinide only promotes the secretion of insulin).

Type 2 diabetes (non-insulin-dependent), the ability of patients with type 2 diabetes to produce insulin is not completely lost, and some patients even produce too much insulin, but the effect of insulin is greatly reduced, so the insulin in the patient may be in a relatively deficient state. This type of diabetes accounts for about 90% of the majority, and the basic ** plan is mainly composed of exercise and diet, but medication** and blood sugar monitoring are often very critical, but in the later stage, it is still controlled by insulin injection.

It's best to go to the hospital and have a look at it and wish it a day**!

Take oral medication and then take insulin after it is not well controlled.

Besides, I have to go to the hospital for diagnosis.

Diabetic type I can only inject insulin, and it makes no sense to take medicine; For diabetes type II (90% of adult patients), oral medications** plus dietary control are preferred, and if ineffective, the insulin injections can be combined with oral hypoglycemic drugs**, which can enhance insulin sensitivity.

Repaglinide (Novosolone): Produced by Novo Nordisk of Denmark, it is the first new oral anti-diabetic drug of the methylmethyl methyl amine benzoic acid family, which can effectively promote insulin secretion, and the binding site on the ATP-sensitive potassium channel of the pancreatic islet cell membrane is completely different from that of sulfonylureas. After oral administration, it can be rapidly absorbed, and the promotion of insulin secretion is relatively fast, but the duration is short, and it has the characteristics of "fast in and fast out", which can simulate physiological insulin secretion in patients with type diabetes, so as to effectively control postprandial hyperglycemia.

Novosolone is mainly metabolized in the liver and is mostly excreted in the feces. In addition, novolone has a high protein binding rate, so it will not accumulate in tissues, and has a good safety profile. Take milligrams of Novosolone daily before three meals a day, lunch and dinner.

The flexible "take medication with meals, without meals without medication" mode can reduce the occurrence of hypoglycemic events, but in the early stage, it is advisable to monitor the patient's blood glucose more closely. The action characteristics and safety of the new insulin secretion promoter novollone can be used alone as a first-line antidiabetic drug in patients with type diabetes who have failed to eat, and it may provide a new means of early imitation for the strengthening of type diabetes.

It is strictly forbidden to use in people with the following symptoms: hypersensitivity to repaglinide or any of the excipients in novo dragon fiber; type diabetes mellitus; diabetic ketoacidosis; Pregnancy or lactation; Children under 12 years of age; Patients with severe renal or hepatic insufficiency; When combined with CYP3A4 inhibitors or inducers**.

Repaglinide hypoglycemic drugs are strictly forbidden for people with the following symptoms: allergy to repaglinide or any of the excipients in Novolone; type diabetes mellitus; diabetic ketoacidosis; Pregnancy or lactation; Children under 12 years of age; Patients with severe renal or hepatic insufficiency; When combined with CYP3A4 inhibitors or inducers**.

The flexible model of "taking medicine with meals, without meals without taking medicine" can reduce the occurrence of hypoglycemia events, but in the early stage, it is advisable to monitor patients' blood glucose more closely. The action characteristics and safety of the new insulin secretion promoter novolone can be used alone as a first-line anti-diabetic drug in patients with type diabetes who have failed to eat, and may provide a new means for the strengthening of type diabetes.